Thrombophilia Due to Factor V and Factor II Mutations and Formation of a Dural Arteriovenous Fistula: Case Report and Review of a Rare Entity

Overview

Journal Skull Base

Date 2008 Sep 5

PMID 18769649

Citations 7

Authors

Sam Safavi-Abbasi

Federico Di Rocco

Peter Nakaji

Guenther C Feigl

Alireza Gharabaghi

Madjid Samii

Anton Valavanis

Amir Samii

Affiliations

Soon will be listed here.

Abstract

Genetic mutations underlying thrombophilia are often recognized in patients with thromboembolic episodes. However, the clinical and therapeutic implications of such findings often remain unclear. We report the first case of a dural arteriovenous fistula (DAVF) in a patient with a combined factor II and factor V Leiden mutation. A 40-year-old man presented with a large left temporal and intraventricular hemorrhage. An initial angiogram showed thrombosis of the left sigmoid sinus but no evidence of a vascular malformation. One year after the hemorrhage, an angiographic study showed the appearance of a right DAVF. During the follow-up period, the patient was found to harbor heterozygosity for a mutation of factor V and a mutation of factor II. Recognition of the patient's thrombophilia led to prolonged oral anticoagulation therapy to reduce the risk of a recurrent thrombotic episode. Despite the increased risk of bleeding, the therapy was considered justified. DAVFs may occur after sinus thrombosis in patients with combined factor II and factor V mutations. This observation indicates the association of multiple hematological disorders with DAVFs in individual patients. Moreover, it raises the clinical conundrum of how to manage patients with thrombophilia, intracranial hemorrhage, and DAVFs.

Citing Articles

Dural arteriovenous fistula disguised as cerebral venous sinus thrombosis.

Sun L, Tang W, Liu L, Wang W, Zhang S, Liu Z J Zhejiang Univ Sci B. 2017; 18(8):733-736.

PMID: 28786250 PMC: 5565523. DOI: 10.1631/jzus.B1600499.

A case of two pial arteriovenous fistulas with giant venous pouches treated by endovascular coil embolization: Therapy with and without anticoagulation.

Ji W, Liu A, Lv X, Li Y, Yang X, Jiang C Interv Neuroradiol. 2015; 22(1):97-100.

PMID: 26647228 PMC: 4757377. DOI: 10.1177/1591019915617322.

Angioarchitectural evolution of clival dural arteriovenous fistulas in two patients.

Pouw A, Rabin R, Karanjia R, Bababeygy S, Amar A, Sadun A Case Rep Ophthalmol. 2015; 6(1):93-100.

PMID: 25873894 PMC: 4386113. DOI: 10.1159/000381176.

Intracranial hypertension and intracranial hypotension causing headache in the same patient.

Panikkath R, Welker J, Johnston R, Lado-Abeal J Proc (Bayl Univ Med Cent). 2014; 27(3):217-8.

PMID: 24982565 PMC: 4059569. DOI: 10.1080/08998280.2014.11929114.

Benign intracranial hypertension: a diagnostic dilemma.

Shaw G, Million S Case Rep Otolaryngol. 2012; 2012:814696.

PMID: 22928139 PMC: 3423822. DOI: 10.1155/2012/814696.

References

Gerlach R, Yahya H, Rohde S, Bohm M, Berkefeld J, Scharrer I . Increased incidence of thrombophilic abnormalities in patients with cranial dural arteriovenous fistulae. Neurol Res. 2003; 25(7):745-8. DOI: 10.1179/016164103101202101. View

Mullan S . Reflections upon the nature and management of intracranial and intraspinal vascular malformations and fistulae. J Neurosurg. 1994; 80(4):606-16. DOI: 10.3171/jns.1994.80.4.0606. View

Terada T, Higashida R, Halbach V, Dowd C, Tsuura M, Komai N . Development of acquired arteriovenous fistulas in rats due to venous hypertension. J Neurosurg. 1994; 80(5):884-9. DOI: 10.3171/jns.1994.80.5.0884. View

Dahlback B . New molecular insights into the genetics of thrombophilia. Resistance to activated protein C caused by Arg506 to Gln mutation in factor V as a pathogenic risk factor for venous thrombosis. Thromb Haemost. 1995; 74(1):139-48. View

Houser O, Campbell J, Campbell R, Sundt Jr T . Arteriovenous malformation affecting the transverse dural venous sinus--an acquired lesion. Mayo Clin Proc. 1979; 54(10):651-61. View

Einhaupl K, Villringer A, Meister W, Mehraein S, Garner C, Pellkofer M . Heparin treatment in sinus venous thrombosis. Lancet. 1991; 338(8767):597-600. DOI: 10.1016/0140-6736(91)90607-q. View

Martinelli I, Sacchi E, Landi G, Taioli E, Duca F, Mannucci P . High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives. N Engl J Med. 1998; 338(25):1793-7. DOI: 10.1056/NEJM199806183382502. View

Rodeghiero F, Tosetto A . Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism. Ann Intern Med. 1999; 130(8):643-50. DOI: 10.7326/0003-4819-130-8-199904200-00004. View

Deschiens M, Conard J, Horellou M, Ameri A, Preter M, Chedru F . Coagulation studies, factor V Leiden, and anticardiolipin antibodies in 40 cases of cerebral venous thrombosis. Stroke. 1996; 27(10):1724-30. DOI: 10.1161/01.str.27.10.1724. View

10.

Gordon I, Shah B, Hardman D, Chameides L . Giant dural supratentorial arteriovenous malformation. AJR Am J Roentgenol. 1977; 129(4):734-6. DOI: 10.2214/ajr.129.4.734. View

11.

De Stefano V, Martinelli I, Mannucci P, Paciaroni K, Rossi E, Chiusolo P . The risk of recurrent venous thromboembolism among heterozygous carriers of the G20210A prothrombin gene mutation. Br J Haematol. 2001; 113(3):630-5. DOI: 10.1046/j.1365-2141.2001.02827.x. View

12.

Price D, Ridker P . Factor V Leiden mutation and the risks for thromboembolic disease: a clinical perspective. Ann Intern Med. 1998; 127(10):895-903. DOI: 10.7326/0003-4819-127-10-199711150-00007. View

13.

Herman J, Spetzler R, Bederson J, Kurbat J, Zabramski J . Genesis of a dural arteriovenous malformation in a rat model. J Neurosurg. 1995; 83(3):539-45. DOI: 10.3171/jns.1995.83.3.0539. View

14.

Bertina R, Koeleman B, Koster T, Rosendaal F, Dirven R, de Ronde H . Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994; 369(6475):64-7. DOI: 10.1038/369064a0. View

15.

Satomi J, van Dijk J, terBrugge K, Willinsky R, Wallace M . Benign cranial dural arteriovenous fistulas: outcome of conservative management based on the natural history of the lesion. J Neurosurg. 2002; 97(4):767-70. DOI: 10.3171/jns.2002.97.4.0767. View

16.

Lanzino G, Jensen M, Kongable G, Kassell N . Angiographic characteristics of dural arteriovenous malformations that present with intracranial hemorrhage. Acta Neurochir (Wien). 1994; 129(3-4):140-5. DOI: 10.1007/BF01406493. View

17.

Zoller B, Garcia de Frutos P, Hillarp A, Dahlback B . Thrombophilia as a multigenic disease. Haematologica. 1999; 84(1):59-70. View

18.

Simioni P, Prandoni P, Lensing A, Manfrin D, Tormene D, Gavasso S . Risk for subsequent venous thromboembolic complications in carriers of the prothrombin or the factor V gene mutation with a first episode of deep-vein thrombosis. Blood. 2000; 96(10):3329-33. View

19.

Koster T, Rosendaal F, de Ronde H, Briet E, Vandenbroucke J, Bertina R . Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet. 1993; 342(8886-8887):1503-6. DOI: 10.1016/s0140-6736(05)80081-9. View

20.

Rees D, Chapman N, Webster M, Guerreiro J, Rochette J, Clegg J . Born to clot: the European burden. Br J Haematol. 1999; 105(2):564-6. View